Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Juventas packs in Parkland-backed round

Nov 20, 2020 • Robert Lavine

The property developer has backed Chinese Academy of Medical Sciences spinout Juventas to help advance its clinical-stage oncology cell therapy candidates.

Juventas, a China-based immunotherapy developer based on research at Chinese Academy of Medical Sciences, raised $65m in funding on Wednesday.
The company did not identify investors, however, DealStreetAsia reported it was led by private equity fund CMG-SDIC Capital and backed by commercial property developer Parkland Group.
The round also included Kaixin Biotechnology – possibly part of automotive retailer Kaixin Auto – Tzitzit Asset, Tianjin Venture Capital, Ruisheng Investment, Xiangrong Capital, Dalton Venture and Jiadao Fanghua Investment.
Parkland took part through its Daxie Pengchuang Investment vehicle. DealStreetAsia reported the round size as RMB450m, which would equate to $68.4m.
Juventas is developing cellular immuno-oncology therapies for acute lymphatic leukaemia and haematologic tumours. It recently began a phase 2 registration study for its lead drug candidate, CNCT19 for relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL).
CNCT19 is also in a phase 1 clinical trial for relapsed or refractory acute lymphoblastic leukaemia, with a phase 2 study expected to begin by the end of this year.
Pharmaceutical company Casi Pharmaceuticals led a $14.5m series A-plus round in July 2019 that also featured Dalton Venture and Panacea Venture, following $23.7m in series A funding from Redhill Capital and Dalton Venture in late 2018.
Wei-Wu He, chairman and CEO of Casi, said in a statement this week: “Its financing provides Juventas with resources to continue moving CNCT19 through registration, and we remain excited about its potential as a first-line treatment for B-NHL.
“In addition, as a large (16%) shareholder of Juventas, we are pleased to see Juventas’ progress in their overall pipeline and expect its financing to help accelerate its development.”
– A version of this article first appeared on our sister site, Global Corporate Venturing.

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
Events
Is now the right time to invest in autonomous driving?
Feb 19, 2025
Online
Events
GCV Connect: São Paulo
Feb 19, 2025
São Paulo (Brazil)
Events
GCV Institute: CVC Investment Programs
Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)
Events
GCVI Summit 2025
Mar 18 -
Mar 20, 2025
Monterey, CA (USA)
Events
GCV Institute: CVC Investment Programs
Apr 8 -
Apr 10, 2025
Online
Events
GCV Institute: Landing the Value of Corporate Venturing
Apr 24 -
Jun 12, 2025
Online
Events
GCV Connect: Madrid 2025
Apr 24, 2025
Madrid (Spain)
Events
GCV Connect: Singapore 2025
May 6, 2025
Singapore
Events
GCV Symposium 2025
Jun 17 -
Jun 19, 2025
London (UK)
© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here